Johnson Johnson Aktie

172,52 EUR +0,38 EUR +0,22 %

12:42:33

XETRA

199,76 USD +0,23 USD +0,12 %

nachbörslich12:33:16

BTT

Johnson Johnson jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.415,17 Mrd. EUR

KGV24,98Div. Rendite3,40%

WKN853260

ISINUS4781601046

SymbolJNJ

Johnson Johnson Aktien News

Sortieren:Datum Meistgelesen

29.10.25finanzen.netFrühe Investition

Dow Jones 30 Industrial-Titel Johnson Johnson-Aktie: So viel Gewinn hätte ein Investment in Johnson Johnson von vor 3 Jahren eingebracht

29.10.25PR NewswireJohnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting

29.10.25EN, Johnson & JohnsonJohnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting

28.10.25finanzen.netDow Jones aktuell: Dow Jones zum Handelsende in der Gewinnzone

28.10.25finanzen.netDienstagshandel in New York: Das macht der Dow Jones nachmittags

28.10.25EN, Johnson & JohnsonJohnson & Johnson to Advance Robotics Development with NVIDIA Isaac for Healthcare

28.10.25finanzen.netBörse New York: So steht der Dow Jones mittags

28.10.25finanzen.netPluszeichen in New York: Dow Jones zum Handelsstart freundlich

27.10.25PR NewswireNew study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile

27.10.25EN, Johnson & JohnsonJohnson & Johnson Advances Polyphonic™ AI Fund for Surgery for Data-Driven Healthcare

27.10.25EN, Johnson & JohnsonNew study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile

27.10.25PR NewswireTREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years

27.10.25PR NewswireIcotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis

27.10.25EN, Johnson & JohnsonIcotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis

27.10.25EN, Johnson & JohnsonTREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn’s disease at two years

25.10.25PR NewswirePublished in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies

25.10.25EN, Johnson & JohnsonPublished in The Lancet: Nipocalimab significantly decreased Sjögren’s disease (SjD) activity and severity through substantial reduction in Sjögren’s-related autoantibodies

24.10.25finanzen.netBörse New York in Grün: Dow Jones schlussendlich fester

24.10.25finanzen.netFreitagshandel in New York: Das macht der Dow Jones nachmittags

24.10.25finanzen.netPluszeichen in New York: Dow Jones mittags freundlich

24.10.25finanzen.netOptimismus in New York: Dow Jones bewegt sich zum Start im Plus

24.10.25EN, Johnson & JohnsonJohnson & Johnson MedTech Highlights Newest Impella Heart Pump and Long-Term Survival Data at TCT 2025

24.10.25EN, Johnson & JohnsonIcotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis

24.10.25PR NewswireIcotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis

22.10.25finanzen.netJohnson Johnson-Investment im Blick

Dow Jones 30 Industrial-Titel Johnson Johnson-Aktie: So viel hätten Anleger an einem Johnson Johnson-Investment von vor einem Jahr verdient

21.10.25finanzen.netDow Jones-Handel aktuell: Dow Jones zum Handelsende fester

21.10.25finanzen.netPluszeichen in New York: So bewegt sich der Dow Jones am Dienstagnachmittag

21.10.25finanzen.netFreundlicher Handel in New York: Anleger lassen Dow Jones steigen

20.10.25finanzen.netBörse New York in Grün: Dow Jones im Aufwind

20.10.25EN, Johnson & JohnsonJohnson & Johnson’s INLEXZO™ (gemcitabine intravesical system) plus cetrelimab delivers strong pre-surgical results in patients with muscle invasive bladder cancer scheduled for radical cystectomy

19.10.25EN, Johnson & JohnsonSubcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer

19.10.25PR NewswireSubcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer

Johnson Johnson News

Johnson Johnson News: auf dieser Seite finden Sie alle Johnson Johnson News und Nachrichten zur Johnson Johnson Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Johnson Johnson News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Johnson Johnson News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.